BIIB
Biogen
Biological Products, (No Diagnostic Substances) · Health Care
$248.93-0.03%
Quote via Yahoo Finance, may be delayed · 2026-11-03 · 4:00 PM ET
Daily prices: Yahoo Finance, split-adjusted. As of 2026-11-03.
Drag across the line to read a price. Dots mark earnings, filings and dividends.
Mixed profile
FCF yield lifts this profile the most.
As of 2025-12-31. Latest quarter ended 2026-09-30. v1 methodology, subject to change.
The profile score is 3 points lower since last quarter. Price is 16 points lower. Growth is 8 points higher.
Sector rank 24 of 46
In plain English
- Biogen operates in Biological Products, (No Diagnostic Substances).
- Latest-year revenue was 9.9 billion.
- The profile score is 53, a Mixed profile. Price is the strongest listed input.
This company's filings do not tag an operating income line, and no total-costs figure exists to derive one. Operating margin, ROIC, margin stability, net debt to EBITDA, interest cover and Altman Z are left blank rather than estimated. Net income, revenue and cash flow come from the filing as reported.
Written from the figures on this page. No language model was called. It may still be wrong. Not advice.
As of 2025-12-31. Latest quarter ended 2026-09-30. SEC EDGAR companyfacts, fetched 2026-11-01. SEC filing
Financials
Tap a column to read the value.
P/E vs own history
Now 105.4 times, 5-year median 18.4 times.
Line is the quarterly multiple. The band is the 25th to 75th percentile of that history. The dashed line is the median.
Earnings
Actual earnings per share from EDGAR filings. Historical estimates are not used.
Actual from EDGAR
Data confidence
The Company Score summarises financial characteristics relative to similar companies using a published formula. It does not predict future returns.
SEC EDGAR companyfacts, fetched 2026-11-01.